Sapropterin (Kuvan): Synthetic form of tetrahydrobiopterin approved for the treatment of PKU

FDA approved sapropterin on December 13, 2007, to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due ro BH4-responsive phenylketonuria (PKU).